December 2020, Vol 10, No 12

Xevinapant, an investigational antagonist of IAPs (inhibitor of apoptosis proteins), prolonged overall survival (OS) in patients with locally advanced head and neck squamous-cell carcinoma (HNSCC) when added to chemoradiotherapy, according to an updated analysis of a phase 2 clinical trial that was presented at the 2020 European Society for Medical Oncology (ESMO) congress. Read More ›

When I was a medical student, one of the attending physicians told me a story about a 25-year veteran nurse known as “Nurse Patty,” who he had worked with when he was a resident. Although most of the employees at the hospital were outstanding, this particular nurse had a reputation for making decisions that were not always medically sound. All of the residents at the hospital knew that when Nurse Patty was on duty, they needed to keep a careful eye on their patients. However, because this nurse had been employed at the hospital for many years, no one—including her—thought she could ever be fired. Read More ›

Helping patients with cancer achieve optimal health status can present special challenges when their basic needs such as food security, housing, and transportation are not being met. If patients are experiencing such social influencers to health, they will often forgo healthcare or become noncompliant with treatment due to lack of resources. Implementing a community health worker program to complement clinical care can help provide compassionate care for the most vulnerable patients and lead to improved outcomes. Read More ›

The following clinical trials represent a selection of key studies currently recruiting patients with bladder cancer for inclusion in investigations of new therapies and new regimens of existing treatments for the disease. Read More ›

Page 2 of 2

Subscribe to
Oncology Practice Management

Stay up to date with oncology news & updates by subscribing to recieve the free OPM print publications or weekly e‑Newsletter.

I'd like to recieve: